© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Cancer Inhibition in Nude Mice After Systemic Application of U6 Promoter–Driven Short Hairpin RNAs Against PLK1
Affiliation of authors: Department of Obstetrics and Gynecology, School of Medicine, J. W. Goethe-University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany
Correspondence to: Professor Dr. K. Strebhardt, School of Medicine, Department of Obstetrics and Gynecology, J. W. Goethe-University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany (e-mail: strebhardt{at}em.uni-frankfurt.de)
Background: RNA interference initiated by small interfering RNAs effectively suppresses gene expression, but the suppression is transient, which limits the therapeutic use of this technique. Polo-like kinase 1 (PLK1) is a key cell cycle regulator that is overexpressed in various human tumors. We used a xenograft mouse model to determine whether an RNA interference–based strategy that used short hairpin RNAs (shRNAs) to suppress PLK1 expression could inhibit tumor growth in vivo. Methods: HeLa S3 cervical and A549 lung cancer cell lines were transfected with plasmids containing U6 promoter–driven shRNAs against human PLK1 or control (parental or scrambled) plasmids. Plasmids were treated with the nuclease inhibitor aurintricarboxylic acid (ATA) as protection against nucleases in murine blood. Nude mice carrying xenograft tumors were injected with shRNA plasmids, and their xenograft tumor growth was assessed. Northern and western blot analyses were used to measure PLK1 mRNA and protein expression, respectively, in transfected cultured cells and in xenograft tumors. All statistical tests were two-sided. Results: Levels of PLK1 mRNA and protein were lower in HeLa S3 and A549 cancer cells transfected with PLK1 shRNA plasmids than in corresponding cells transfected with control parental or scrambled PLK1S shRNA plasmids. Proliferation of cells transfected with PLK1 shRNA was lower than that of cells transfected with either control plasmid, and proliferation of cells transfected with ATA-treated PLK1 shRNA plasmids was even lower. In mice with human xenograft tumors, PLK1 shRNA expression from ATA-treated plasmids reduced tumor growth to 18% (95% confidence interval [CI] = 12% to 26%; P = .03) and from untreated plasmids reduced tumor growth to 45% (95% CI = 26% to 64%; P = .1) of that of tumors in mice treated with scrambled control PLK1S shRNA plasmids. Conclusions: The combination of shRNA-mediated gene silencing with effective in vivo gene delivery strategies appears to generate a long-lasting silencing signal.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Jimeno, J. Li, W. A. Messersmith, D. Laheru, M. A. Rudek, M. Maniar, M. Hidalgo, S. D. Baker, and R. C. Donehower Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors J. Clin. Oncol., December 1, 2008; 26(34): 5504 - 5510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Olmos, C. Swanton, and J. de Bono Targeting Polo-Like Kinase: Learning Too Little Too Late? J. Clin. Oncol., December 1, 2008; 26(34): 5497 - 5499. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bulk, A. Hascher, R. Liersch, R. M. Mesters, S. Diederichs, B. Sargin, V. Gerke, M. Hotfilder, J. Vormoor, W. E. Berdel, et al. Adjuvant Therapy with Small Hairpin RNA Interference Prevents Non-Small Cell Lung Cancer Metastasis Development in Mice Cancer Res., March 15, 2008; 68(6): 1896 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, L. Gao, L. Zhao, B. Guo, K. Ji, Y. Tian, J. Wang, H. Yu, J. Hu, D. V. Kalvakolanu, et al. Intratumoral Delivery and Suppression of Prostate Tumor Growth by Attenuated Salmonella enterica serovar typhimurium Carrying Plasmid-Based Small Interfering RNAs Cancer Res., June 15, 2007; 67(12): 5859 - 5864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jagannath and M. Wood RNA interference based gene therapy for neurological disease Brief Funct Genomic Proteomic, May 3, 2007; (2007) elm005v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Lansing, R. T. McConnell, D. R. Duckett, G. M. Spehar, V. B. Knick, D. F. Hassler, N. Noro, M. Furuta, K. A. Emmitte, T. M. Gilmer, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 Mol. Cancer Ther., February 1, 2007; 6(2): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kappel, Y. Matthess, B. Zimmer, M. Kaufmann, and K. Strebhardt Tumor inhibition by genomically integrated inducible RNAi-cassettes Nucleic Acids Res., September 11, 2006; 34(16): 4527 - 4536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Spankuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, J. Yuan, M. Kaufmann, and K. Strebhardt Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo Cancer Res., June 1, 2006; 66(11): 5836 - 5846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shi, M. Zou, K. Collison, E. Y. Baitei, Z. Al-Makhalafi, N. R. Farid, and F. A. Al-Mohanna Ribonucleic Acid Interference Targeting S100A4 (Mts1) Suppresses Tumor Growth and Metastasis of Anaplastic Thyroid Carcinoma in a Mouse Model J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2373 - 2379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, M. Lei, and R. L. Erikson Normal cells, but not cancer cells, survive severe plk1 depletion. Mol. Cell. Biol., March 1, 2006; 26(6): 2093 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Takeshita, Y. Minakuchi, S. Nagahara, K. Honma, H. Sasaki, K. Hirai, T. Teratani, N. Namatame, Y. Yamamoto, K. Hanai, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo PNAS, August 23, 2005; 102(34): 12177 - 12182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Guan, P. Tapang, J. D. Leverson, D. Albert, V. L. Giranda, and Y. Luo Small Interfering RNA-Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals Cancer Res., April 1, 2005; 65(7): 2698 - 2704. [Abstract] [Full Text] [PDF]
|
|